• MetaVia flagged new Phase 1 higher-dose cohort results for its obesity drug candidate DA-1726, with data slated for presentation at the American Diabetes Association’s 2026 Scientific Sessions on June 7.
• The readout is positioned to clarify whether the dual GLP-1/glucagon program can support higher dosing with improved tolerability, a key step toward differentiation in the obesity market.
• Two additional late-breaking posters will present preclinical work on vanoglipel, pointing to potential synergy in combinations aimed at MASH and Type 2 diabetes.
• The conference disclosures set up a near-term catalyst cycle for the pipeline, with the company also targeting a separate update from an ongoing 16-week Phase 1 titration study in the fourth quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605180831PR_NEWS_USPR_____NY61026) on May 18, 2026, and is solely responsible for the information contained therein.